Given that ESR1 alterations are typically linked with treatment resistance and are found very infrequently (approximately 3%) in primary breast cancers,61 the ratio of treatment-naive to treatment-exposed patients may have skewed our analysis. Here, ESR1 is linked to breast carcinoma.